Diabetic retinopathy - ocular complications of diabetes mellitus.
暂无分享,去创建一个
[1] M. Ulbig,et al. The therapeutic potential of intraocular depot steroid systems: developments aimed at prolonging duration of efficacy. , 2012, Deutsches Arzteblatt international.
[2] R. Klein,et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials , 2008, The Lancet.
[3] J. Olson,et al. Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme , 2013, Diabetologia.
[4] M. Postorino,et al. Dexamethasone Intravitreal Implant for Treatment of Patients with Persistent Diabetic Macular Edema , 2013, Ophthalmologica.
[5] A. Kampik,et al. ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION: Decreasing Incidence and Clinical Outcome—8-year Results from a Tertiary Ophthalmic Referral Center , 2014, Retina.
[6] Philip D. Harvey,et al. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 , 1998, BMJ.
[7] F. Fajnkuchen,et al. ANTI-VEGF THERAPY FOR DIABETIC MACULAR EDEMA Anti-VEGF Therapy For Diabetic Macular Edema , 2015 .
[8] Risk stratification for diabetic eye screening , 2013, Diabetologia.
[9] H. Ahsan. Diabetic retinopathy--biomolecules and multiple pathophysiology. , 2015, Diabetes & metabolic syndrome.
[10] W. Rathmann,et al. Epidemiologie und Verlauf des Diabetes mellitus in Deutschland , 2004 .
[11] Lloyd Paul Aiello,et al. Nonmydriatic ultrawide field retinal imaging compared with dilated standard 7-field 35-mm photography and retinal specialist examination for evaluation of diabetic retinopathy. , 2012, American journal of ophthalmology.
[12] Laurel Beckett,et al. Reproducibility of macular thickness measurement among five OCT instruments: effects of image resolution, image registration, and eye tracking. , 2012, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.
[13] Nationale Versorgungsleitlinie Typ-2-Diabetes – Prävention und Therapie von Netzhautkomplikationen , 2006 .
[14] Norman Fleischer,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. , 1993 .
[15] Marco A Zarbin,et al. Diabetic macular edema: pathogenesis and treatment. , 2009, Survey of ophthalmology.
[16] K. Lemmen. Medikamentöse Therapie der diabetischen Retinopathie und Makulopathie , 2008, Der Diabetologe.
[17] A. Kampik,et al. Assessment of Diabetic Retinopathy Using Nonmydriatic Ultra-Widefield Scanning Laser Ophthalmoscopy (Optomap) Compared With ETDRS 7-Field Stereo Photography , 2012, Diabetes Care.
[18] C. Bührer,et al. Diabetes und Schwangerschaft , 2008 .
[19] A. Sjølie,et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes , 1998, The Lancet.
[20] G. Roglić,et al. Screening intervals for diabetic retinopathy and incidence of visual loss: a systematic review , 2013, Diabetic medicine : a journal of the British Diabetic Association.
[21] A. Sjølie,et al. Is Smoking a Risk Factor for Proliferative Diabetic Retinopathy in Type 1 Diabetes? , 2013, Ophthalmologica.
[22] H. Flynn,et al. ENDOPHTHALMITIS ASSOCIATED WITH INTRAVITREAL INJECTIONS: Office-Based Setting and Operating Room Setting , 2014, Retina.
[23] A. Harris,et al. Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant , 2014, Expert opinion on pharmacotherapy.
[24] T Bek,et al. Screening and prevention of diabetic blindness. , 2000, Acta ophthalmologica Scandinavica.
[25] P. Keane,et al. RISK FACTORS FOR PROLIFERATIVE DIABETIC RETINOPATHY IN A LATINO AMERICAN POPULATION , 2012, Retina.
[26] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[27] B. Rhee,et al. Prevalence and factors associated with diabetic retinopathy in a Korean adult population: the 2008-2009 Korea National Health and Nutrition Examination Survey. , 2013, Diabetes research and clinical practice.
[28] E. Stefánsson,et al. Biennial eye screening in patients with diabetes without retinopathy: 10-year experience , 2007, British Journal of Ophthalmology.
[29] G. Yancopoulos,et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. , 2001, Investigative ophthalmology & visual science.
[30] M. Maia,et al. Anti-VEGF for the Management of Diabetic Macular Edema , 2014, Journal of immunology research.
[31] T. Gardner,et al. Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment , 2014, Annals of the New York Academy of Sciences.
[32] H. Novotny,et al. A Method of Photographing Fluorescence in Circulating Blood in the Human Retina , 1961, Circulation.
[33] M. Grueterich,et al. Application of 10% Povidone Iodine Reduces Conjunctival Bacterial Contamination Rate in Patients Undergoing Cataract Surgery , 2012, European journal of ophthalmology.
[34] J. Kerrison,et al. Metabolic control and diabetic retinopathy. , 2009, Current diabetes reviews.
[35] R. Schlingemann,et al. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions , 2013, Progress in Retinal and Eye Research.
[36] R. Retnakaran,et al. Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial , 2013, Diabetic medicine : a journal of the British Diabetic Association.
[37] J. Gross,et al. Diabetic Retinopathy Predicts All-Cause Mortality and Cardiovascular Events in Both Type 1 and 2 Diabetes , 2011, Diabetes Care.
[38] Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. , 1991, Ophthalmology.
[39] Thomas W. Gardner,et al. The restore study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema , 2011 .
[40] J. C. Gines,et al. Bakterielle Kontamination von Injektionskanülen nach intravitrealer operativer Medikamenteneingabe in Paraguay , 2012, Der Ophthalmologe.
[41] Szilárd Kiss,et al. ULTRA–WIDE-FIELD ANGIOGRAPHY IMPROVES THE DETECTION AND CLASSIFICATION OF DIABETIC RETINOPATHY , 2012, Retina.
[42] J. Shaw,et al. Global estimates of the prevalence of diabetes for 2010 and 2030. , 2010, Diabetes research and clinical practice.
[43] A. Sjølie,et al. Proliferative retinopathy predicts nephropathy: a 25-year follow-up study of type 1 diabetic patients , 2012, Acta Diabetologica.
[44] H. Hammes. Optimal treatment of diabetic retinopathy , 2013, Therapeutic advances in endocrinology and metabolism.
[45] E. Stefánsson,et al. Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy , 2011, Diabetologia.
[46] T. Krohne,et al. Diabetische Retinopathie , 2003, Der Ophthalmologe.
[47] M. Nentwich,et al. Diabetes und Auge , 2014, Der Diabetologe.
[48] Elena Prokofyeva,et al. Epidemiology of Major Eye Diseases Leading to Blindness in Europe: A Literature Review , 2011, Ophthalmic Research.
[49] A. Kampik,et al. Bacterial Contamination of Needle Points after Intravitreal Injection , 2009, European journal of ophthalmology.
[50] B. Godley,et al. Nicotine Accelerates Diabetes-Induced Retinal Changes , 2015, Current eye research.
[51] S. Genuth,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.
[52] T. Sørensen,et al. NO CASES OF ENDOPHTHALMITIS AFTER 20,293 INTRAVITREAL INJECTIONS IN AN OPERATING ROOM SETTING , 2014, Retina.
[53] S. Whitcup,et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. , 2014, Ophthalmology.
[54] D. Park,et al. COMPARISON OF CLINICAL OUTCOMES BETWEEN 23-GAUGE AND 20-GAUGE VITRECTOMY IN PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY , 2010, Retina.
[55] Bing Li,et al. Comparison of the efficacy of povidone–iodine 1.0%, 5.0%, and 10.0% irrigation combined with topical levofloxacin 0.3% as preoperative prophylaxis in cataract surgery , 2013, Journal of cataract and refractive surgery.
[56] F. Verbraak. Neuroretinal Degeneration in Relation to Vasculopathy in Diabetes , 2014, Diabetes.
[57] Lala Ceklic,et al. Nonmydriatic Ultra-Wide-Field Scanning Laser Ophthalmoscopy (Optomap) versus Two-Field Fundus Photography in Diabetic Retinopathy , 2013, Ophthalmologica.
[58] E. Vaucher,et al. The kallikrein-kinin system in diabetic retinopathy. , 2014, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.
[59] H. Parving,et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial , 2008, The Lancet.
[60] P. Campochiaro,et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. , 2012, Ophthalmology.
[61] A. Wenzel,et al. [Diabetic maculopathy and retinopathy. Functional and sociomedical significance]. , 2010, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.